Last reviewed: July 8, 2026 Last updated: July 8, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Pharmacoepidemiologist Serena Jingchuan Guo wonders if the drug could one day be used before addiction sets in, for instance as part of a pain management plan for patients prescribed opioids for pain relief after surgery
It is not a substitute for, and is not equivalent to, any FDA-approved tirzepatide product
Risk factors include age over 65 years, history of peptic ulcer disease, concurrent use of anticoagulants or corticosteroids, and prolonged NSAID therapy